QHQianyun He

Qianyun He

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Qianyun He has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Daqiao Zhu

    School of Nursing, Shanghai Jiao Tong University, Shanghai, China

    1 shared publication
  • Dongliang Mao

    Department of Oncology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    1 shared publication
  • Jian Li

    Affiliation Clinical Research Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    1 shared publication
  • Jie Zhang

    Department of Nursing, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    1 shared publication
  • Lei Huang

    Department of Gastroenterology, National Clinical Research Center for Digestive Diseases, The First Affiliated Hospital of Naval Medical University/Changhai Hospital, Naval Medical University, Shanghai 200433, China; National Key Laboratory of Immunity and Inflammation, Changhai Clinical Research Unit, The First Affiliated Hospital of Naval Medical University/Changhai Hospital, Naval Medical University, Shanghai 200433, China

    1 shared publication
  • Mei Wang

    Department of Oncology, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, Shanghai, China

    1 shared publication

Latest Publications

  • Core symptoms in patients with colorectal cancer receiving chemotherapy: a network analysis

    by Jie Zhang, Qianyun He, Mei Wang, Xiaonan Lv, Dongliang Mao, Jian Li, Daqiao Zhu, Lei Huang

    Objective To investigate the prevalence and intensity of symptoms in patients with colorectal cancer (CRC), and to develop a symptom network model to pinpoint key symptoms and clusters within the network. Methods This study encompassed 330 patients receiving postoperative treatment for CRC at a tertiary hospital's oncology department in Shanghai, China, from March 2023 to March 2024. Symptom assessment was conducted using the Chinese version of the MD Anderson Symptom Assessment Scale (MDASI-C) and a specially designed CRC module. Exploratory factor analysis was utilized to identify symptom clusters, and R 4.3.1 software was employed to construct networks of symptom severity and clusters. Centrality indicators, including strength, closeness, and betweenness, were subsequently analyzed to identify core symptoms and clusters. Results Among CRC symptoms, altered bowel habits were the most prevalent (n = 289, 87.6%), followed by distress (n = 250, 75.8%), pain (n = 244, 73.9%), weight loss (n = 205, 62.1%), and fatigue (n = 187, 56.7%). Three primary symptom clusters emerged: The gastrointestinal-neurological cluster, the sickness behavior cluster, and the emotional cluster (variance contribution rate, 36.8%, 19.0%, and 12.3%, respectively; cumulative, 68.1%). In the symptom severity network, numbness exhibited the highest expected influence (rE = 1.25); in the symptom cluster network, numbness (rs = 0.60), sadness (rs = 0.56), and fatigue (rs = 0.55) were the most influential symptoms across the three clusters. Conclusion In patients with CRC undergoing chemotherapy, network analysis identified numbness (gastrointestinal-neurological cluster), sadness (emotional cluster), and fatigue (sickness behavior cluster) as core symptoms, with numbness demonstrating the highest expected influence. The gastrointestinal-neurological cluster emerged as the most central. Strong symptom correlations (e.g., fear-sadness and numbness-sleep disturbance) underscored interconnected physical and psychological burdens. These findings advocate for prioritized targeted interventions: neurotoxicity monitoring for numbness, psychological support for emotional distress, and tailored fatigue management. A multidisciplinary approach is critical to address these interconnected clusters. Future research should employ longitudinal designs to unravel temporal symptom dynamics and refine personalized care.